A5025448721- Multiple Myeloma Research and Treatments
- Chronic Myeloid Leukemia Treatments
- Protein Degradation and Inhibitors
- Cancer Treatment and Pharmacology
- Glycosylation and Glycoproteins Research
- Chronic Lymphocytic Leukemia Research
- Monoclonal and Polyclonal Antibodies Research
- Cancer therapeutics and mechanisms
- Peptidase Inhibition and Analysis
- Acute Myeloid Leukemia Research
- Amyloidosis: Diagnosis, Treatment, Outcomes
- HER2/EGFR in Cancer Research
- Ubiquitin and proteasome pathways
- Quinazolinone synthesis and applications
- Chemokine receptors and signaling
- Histiocytic Disorders and Treatments
- Lymphoma Diagnosis and Treatment
- Uterine Myomas and Treatments
- Soft tissue tumors and treatment
- Platelet Disorders and Treatments
- Circular RNAs in diseases
- Genomic variations and chromosomal abnormalities
- Blood disorders and treatments
- Dendrimers and Hyperbranched Polymers
- Myeloproliferative Neoplasms: Diagnosis and Treatment
Beijing Tsinghua Chang Gung Hospital
2022-2024
Tsinghua University
2022-2024
Institute of Hematology & Blood Diseases Hospital
2017-2024
Chinese Academy of Medical Sciences & Peking Union Medical College
2019-2024
Academy of Medical Sciences
2019
Zhejiang University
2009
Abstract Current standard predictive models of disease risk do not adequately account for the heterogeneity survival outcomes in patients with new‐diagnosed multiple myeloma (NDMM). In this retrospective, multicohort study, we collected clinical and genetic data from 1792 NDMM identified prognostic impact all features. Using top‐ranked features, a weighted Myeloma Prognostic Score System (MPSS) model was formulated validated to predict overall (OS). training cohort, elevated lactate...
Abstract Anaemia is the most common complication of myeloma and associated with worse clinical outcomes. Although marrow replacement cells widely considered a mechanistic rationale for anaemia, exact process has not been fully understood. Our large cohort 1363 patients had more than 50% moderate or severe anaemia at time diagnosis. positively correlated cell infiltration in bone (BM) patient The quantity erythroid differentiation HSPCs were affected by BM. master regulators erythropoiesis,...
Chromosome 1q21 aberrations in multiple myeloma have attracted much attention for a long time, however, the prognostic value is still under investigation. We confirmed independent impact of this non-randomized clinical study. Our study noted that additional copies and larger clonal size gain did not worsen outcome. discovered was associated with acquisition new chromosome abnormalities genomic instability, evidenced by strong correlation between complex karyotypes or more than two...
Schnitzler syndrome is a rare adult-onset acquired autoinflammatory disorder typically characterized by chronic urticarial rash and immunoglobulin M (IgM) (rarely IgG) monoclonal gammopathy. Its clinical symptoms usually respond well to interleukin-1 blockade therapy, which, however, does not impact the underlying Herein, we described female patient who presented with rash, recurrent fevers, fatigue for 7 years. Laboratory investigations revealed IgMκ protein MYD88 L265P mutation, but no...
Attaining undetectable minimal residual disease (MRD) is the current therapeutic goal for multiple myeloma. But there a lack of data regarding clinical benefit autologous stem cell transplantation (ASCT) patients with myeloma achieving early MRD-negative status after induction treatment, in addition to interaction longitudinal MRD ASCT. The study included 407 transplant-eligible available from National Longitudinal Cohort Hematological Diseases China (NCT04645199), whom 147 (34.4%) achieved...
Abstract Background In multiple myeloma (MM), impact of specific chromosomal translocations involving IgH (14q21 locus, including t(4;14), t(11;14), and t(14;16)) has been explored extensively. However, over 15% MM patients harboring translocation with undefined partners have long ignored. Methods A prospective non‐randomized cohort study a total 715 newly‐diagnosed cases was conducted, 13.6% whom were t(14;undefined) positive. The whole divided into four groups: no split (47.7%); (13.6%);...
OBJECTIVE To summarize and compare the clinical baseline characteristics of patients with monoclonal gammopathy undetermined significance (MGUS), primary light chain amyloidosis (pAL), multiple myeloma (MM), or MM concurrent amyloidosis, especially differences in cytogenetic abnormalities. METHODS The data 15 cases MGUS, 34 pAL, 842 23 were analyzed compared retrospectively. RESULTS Cytogenetic statistics showed that incidence t (11; 14) four groups (MGUS vs pAL amyloidosis) was 0%, 33.3%,...
Objective To explore the prognostic impact of miR137 target gene Kruppel-like transcription factor 12(KLF12) in multiple myeloma (MM). Methods The genes were predicted by software. The GFP analysis KLF12 and prognosis MM constructed. Overexpressing NCI-H929 cell line was also Real-time qPCR Western blot used to detect expression this line. Results The MITF, BUE2H, SH3BP5 KLF12. High 455 patients included 75 (16.5 %) died, 104 with low KLF12, 25 (24.0 but no significance detected...
Background: Multiple myeloma (MM) has been linked to the presence of several immunosuppressive monocyte-derived cells within tumor microenvironment (TME), such as osteoclasts, dendritic cells, and macrophages. Nevertheless, association between monocytes themselves immunosuppression context MM received limited investigation thus far.Methods: In this study, we employed single-cell RNA sequencing (scRNA-seq) construct a comprehensive map derived from peripheral blood (PB) bone marrow (BM)...
<p>The prognostic impact of ASCT among all patients</p>
<p>Patient and Treatment Characteristics in ASCT cohort: Sustained MRD-negative vs. MRD-positive</p>
<p>Subgroup analyses for prognostic impact of ASCT</p>
<p>Univariate analyses of PFS and OS in 407 transplant-eligible myeloma patients</p>
<p>The impact of continued MRD-negative status (≥2 years) on PFS</p>
<p>Patient Characteristics, Treatments, and MRD detective methods: ASCT vs. Non-ASCT</p>